Cancer-related mortality among people with intellectual disabilities: A nationwide population-based cohort study

Maarten Cuypers, PhD; Bianca W. M. Schalk, PhD; Anne J. N. Boonman, MSc; Jenneken Naaldenberg, PhD; and Geraline L. Leusink, MD, PhD

BACKGROUND: Concerns have been raised about access to cancer screening and the timely receipt of cancer care for people with an intellectual disability (ID). However, knowledge about cancer mortality as a potential consequence of these disparities is still limited. This study, therefore, compared cancer-related mortality patterns between people with and without ID. METHODS: A historical cohort study (2015-2019) linked the Dutch adult population (approximately 12 million people with an ID prevalence of 1.45%) and mortality registries. Cancer-related mortality was identified by the underlying cause of death (according to the chapter on neoplasms in the International Classification of Diseases, Tenth Revision). Observed mortality and calculated age- and sex-standardized mortality ratios (SMRs) with 95% confidence intervals (CIs) were reported. RESULTS: There were 11,102 deaths in the ID population (21.7% cancer-related; n = 2408) and 730,405 deaths in the general population (31.2%; n = 228,120) available for analysis. Cancer was noted as the cause of death more often among people with ID in comparison with the general population (SMR, 1.48; 95% CI, 1.42-1.54), particularly in the young age groups. High-mortality cancers included cancers within the national screening program (SMRs, 1.43-1.94), digestive cancers (SMRs, 1.24-2.56), bladder cancer (SMR, 2.07; 95% CI, 1.61-2.54), and cancers of unknown primary (SMR, 2.48; 95% CI, 2.06-2.89). CONCLUSIONS: Cancer was reported as the cause of death approximately 1.5 times more often in people with ID compared with the general population. This mortality disparity may indicate adverse effects from inequalities in screening and cancer care experienced by people with ID.

Lay Summary:
- People with an intellectual disability (ID) may find it challenging to participate in cancer screening or to receive timely cancer care.
- To understand potential consequences in terms of mortality, this study compared cancer-related mortality between people with and without ID in the Netherlands.
- Cancer was reported as the cause of death approximately 1.5 times more often among people with ID than others.
- Because large differences were found that were related to screening cancers and cancers for which the primary tumor was unknown, this study’s results raise concerns about equality in screening practices and cancer care for people with ID.

Keywords: cancer, cause of death, disparities, intellectual disability, population-based, standardized mortality ratio.

INTRODUCTION
Patterns of cancer mortality are generally well documented and provide insight into the impact of cancer at the population level, the effectiveness of preventive (public health) measures, and the quality of cancer care. Knowledge of cancer mortality among people with an intellectual disability (ID), however, is neither complete nor up to date. Individuals with ID have significant impairments in intelligence and social functioning, which are often caused by genetic mutations, and they account for at least 1.5% of the population in Western countries. Tumor growth propensities of some ID syndromes could put people with ID at a higher risk of developing certain types of cancer. Other risk factors (eg, lifestyle and external factors) are as equally likely to appear among people with ID as among other people, although differences in the age structure of the intellectual disability population (IDpop) with respect to the general population complicate the interpretation of cancer incidence rates.

For their cancer care, people with ID rely in most countries, including the Netherlands, on the same health care systems as people from the general population. This requires care providers to adapt to the specific care needs of people with ID. Moreover, the recognition of cancer symptoms in individuals with ID may be overshadowed by the manifestation of ID traits or asymptomatic presentation of cancer symptoms. Combined with a lower likelihood...
of participation in cancer screening, this raises concerns about the accessibility and effectiveness of cancer diagnostics and care for people with ID. Even within health systems that strive for broad accessibility and equitable care, such disparities in cancer care can occur.

For evaluating the overall effectiveness of public health care for people with ID, mortality statistics have become an important source of information. It has, among others, identified elevated risks for premature and potentially avoidable mortality in comparison with the general population. To improve our insight into the impact of cancer among people with ID, this study aimed to characterize cancer-related mortality in Dutch individuals with ID in comparison with the general population.

MATERIALS AND METHODS

Setting and Design
This historical cohort study (2015-2019) used administrative data linked at the individual level with nonpublic microdata from Statistics Netherlands. Upon request, these microdata are accessible for statistical and scientific research. We combined databases containing personal information (date of birth and sex), information on ID-related supportive care use, and mortality statistics (date and underlying cause of death). Under Dutch law, large-scale anonymous database studies and posthumous investigations of mortality data are exempted from formal ethical approval. This was confirmed by an assessment of the study protocol by the Radboud University Medical Center institutional ethics committee (2017-3921).

Study Population
Data from the Dutch population register were retrieved for all individuals who were alive and 18 years old or older on January 1, 2015. Individuals with ID were identified through linkage with national databases for chronic care and social benefits. All recipients of ID-related services through any of these systems were classified by the characteristics of their supportive needs because the actual ID diagnoses are not saved in these databases. These data on ID-related care needs are available from 2015 onward. Three ID subgroups were generated: 1) those receiving residential ID care (least independent), 2) those receiving nonresidential ID-related chronic care (moderately independent), and 3) a group with mild ID consisting of those receiving social benefits rather than chronic care (fairly independent). This method for identifying individuals with ID in population data has been described in more detail elsewhere and has been applied to other studies related to health and ID before. All individuals without ID characterization were analyzed as members of the general population.

Outcome Measure
The main outcome in this study was mortality, which consisted of the date of death and the underlying cause coded according to the International Classification of Diseases, Tenth Revision (ICD-10). Cancer-specific mortality was defined according to the chapter on neoplasms (codes C00-D48; see Supporting Table 1). Within the chapter on neoplasms, we categorized according to the 18 predefined groups (eg, “malignant neoplasms of lip, oral cavity, and pharynx” [C00-C14]) and reported individual cancer types by their 3-position ICD-10 code (eg, “C15–malignant neoplasm of esophagus”).

Statistical Analysis
We calculated the age at death by subtracting the date of birth from the date of death. Demographics were presented as frequencies (with percentages) or means (with standard deviations). We reported observed deaths for both groups, and we calculated expected deaths for each sex and 10-year age group in the IDpop on the basis of mortality in the same group from the general population. Age- and sex-standardized mortality ratios (SMRs) were then generated by the division of observed mortality by expected mortality, and they were presented with 95% confidence intervals (CIs). SMRs higher than 1.0 indicated increased mortality risks for the ID population, and SMRs less than 1.0 indicated lower risks. Analyses were conducted for overall mortality, cancer-related mortality, and cancer type-specific mortality for the most common causes. Data quality checks and missing data analysis were conducted at Statistics Netherlands before the data were made available for further analysis. Analyses were conducted with SPSS 25.

RESULTS

Demographics and Overall Mortality
Through linking databases, 187,149 adults with an ID (the IDpop) were identified (ID prevalence, 1.45%) at the start of follow-up in 2015, and the remaining 12,677,768 individuals without ID were assumed to constitute the general Dutch adult population (the GenPop). The mean age was 8.7 years lower in the IDpop than the GenPop (39.6 vs 48.3 years). The IDpop had more males (57.4%) than the GenPop (48.9%). The largest group in the IDpop consisted of recipients of...
residential ID care (n = 91,064; 48.7%), and they were followed by people with mild ID (n = 69,078; 36.9%) and nonresidential chronic care users (n = 27,007; 14.4%). A complete overview of all demographics is presented in Table 1.

During follow-up, 11,102 deaths (all causes) were counted in the IDpop, and 730,405 deaths were counted in the GenPop. The mean age at death was 15.6 years lower in the IDpop than the GenPop (63.2 vs 78.8 years). Mortality was higher in the IDpop than the GenPop (SMR, 2.71; 95% CI, 2.66–2.76). SMRs declined with increasing independence across ID subgroups (Table 1).

### Cancer Mortality
Cancer was the most common cause of death in the IDpop (22.4% of all deaths), and it was followed by circulatory (20.2%) and respiratory causes (12.7%); this made the top 3 causes of death in terms of ICD-10 chapters similar to the GenPop. At the IDpop level, there were 785 more deaths due to cancer during follow-up than expected on the basis of cancer mortality in the GenPop (SMR, 1.48; 95% CI, 1.42–1.54; Table 2). Individuals with ID who died of cancer were 10.7 years younger than individuals who died of cancer in the GenPop (62.9 vs 73.6 years; Table 2).

All cancer types within the national screening program (colon, breast, and cervix) caused more deaths among people with ID than expected on the basis of mortality in the GenPop, with colon cancer causing the most deaths in absolute numbers (n = 200; SMR, 1.66; 95% CI, 1.43–1.89) and with cervical cancer causing the largest difference in comparison with GenPop (SMR, 1.94; 95% CI, 1.02–2.86), even though only 17 deaths from this cause appeared during follow-up in the IDpop. Breast cancer fell between them in terms of both absolute and relative mortality (n = 151; SMR, 1.43; 95% CI, 1.21–1.66; Table 3). By volume, lung cancer was the most common cancer-related cause of death in the IDpop (n = 493; SMR, 1.24; 95% CI, 1.13–1.35). The largest differences in comparison with the GenPop were related to cancers of unknown primary (SMR, 2.48; 95% CI, 2.06–2.89) and other (not colon) digestive organs (SMR, 2.65; 95% CI, 2.06–3.25). Among the most common cancer-related causes of death, prostate cancer did not cause elevated mortality in the IDpop in comparison with the GenPop (SMR, 0.91; 95% CI, 0.70–1.12; Table 3).

### DISCUSSION
This study is the first to characterize cancer-related mortality among adults with ID by using population data. Even though life expectancy is lower for people with ID than the general population, we have shown that cancer is the most prominent cause of death for people with ID as well. Although excess mortality due to cancer was less pronounced in comparison with other causes of death, still almost 800 more people with ID died of cancer during the study period than expected on the basis of cancer-related mortality among people of the same age and sex in the general population. This could be the result of 1) a higher overall incidence of cancer among people with ID; 2) a higher incidence of lethal cancers in particular; or 3) less effective cancer care for people with ID, including prevention and screening policies.

First, we consider the possibility of a higher overall incidence of cancer among people with ID. So far, most studies have reported a lower or similar overall cancer incidence among people with ID in comparison with people without ID. Even at older ages, the frequency of cancer diagnoses among people with ID appears to be lower in comparison with the general population. Specific ID syndromes may be associated with increased risks for certain cancers. For example, Down syndrome is associated with an increased risk for leukemia, yet it is also associated with a reduced risk for solid tumors. Although complete information on all genetic ID syndromes with tumor growth propensities is missing to date, these subpopulations appear too small to explain the differences in mortality detected in this study.

Second, lethal cancers in particular could be more prevalent among people with ID than people without ID. There were relatively many deaths due to cancers of unknown primary in the IDpop, and these cancers are often characterized by the presence of metastases at diagnosis and an absence of targeted therapies. There were also more deaths from esophageal cancer and digestive cancers in the IDpop than expected. In particular, for advanced stages of these cancers, survival rates beyond the first year after diagnosis are below 50%, and 5-year survival is rare. Risk factors for these cancers include smoking, substance abuse, and poor nutrition, which are all relatively common in certain ID subgroups. Another risk factor for gastrointestinal malignancies is *Helicobacter pylori* infection, which has been reported to occur twice as often among people with ID in comparison with the general population. Moreover, people with ID could be more susceptible to complications after treatment for gastrointestinal malignancies because of their generally greater likelihood...
# TABLE 1. Demographics and Overall Mortality (All Causes), 2015-2019

| ID group | GenPop (n = 12,677,678) | IDpop (n = 187,149) | SMR | 95% CI |
|----------|------------------------|---------------------|-----|--------|
|          | Population, No. (%)    | Observed Deaths, No. (Rate)<sup>a</sup> | Population, No. (%) | Observed Deaths, No. (Rate)<sup>a</sup> | Expected Deaths, No. | SMR | 95% CI |
| Total No. | 12,677,768              | 730,405 (115.2)     | 187,149 | 11,102 (118.6) | 4093 | 2.71 | 2.66-2.76 |
| Sex       |                        |                     |       |                     |     |       |       |
| Males     | 6,196,789 (48.9)        | 352,224 (113.7)     | 107,370 (57.4) | 6323 (117.8) | 2515 | 2.51 | 2.45-2.58 |
| Females   | 6,480,979 (51.1)        | 378,181 (116.7)     | 78,779 (42.6) | 4779 (119.8) | 1578 | 3.03 | 2.94-3.11 |
| Age, mean (SD), y | 48.3 (17.8) | 39.6 (15.6) |     |                     |     |       |       |
| Age at enrollment |                |                     |       |                     |     |       |       |
| 18-24 y   | 1,362,047 (10.7)        | 1962 (2.9)          | 44,343 (23.7) | 282 (12.7) | 67   | 4.21 | 3.71-4.70 |
| 25-34 y   | 1,931,948 (15.2)        | 4456 (4.6)          | 36,615 (19.6) | 390 (2.1) | 87   | 4.49 | 4.05-4.94 |
| 35-44 y   | 2,225,395 (17.6)        | 12,797 (11.9)       | 32,514 (17.4) | 830 (5.1) | 191  | 4.35 | 4.05-4.65 |
| 45-54 y   | 2,457,868 (19.4)        | 39,033 (31.8)       | 37,109 (19.8) | 2371 (127.8) | 600  | 3.95 | 3.79-4.11 |
| 55-64 y   | 2,104,631 (16.6)        | 89,895 (85.4)       | 25,140 (13.4) | 3490 (277.6) | 1110 | 3.14 | 3.04-3.25 |
| 65-74 y   | 1,551,963 (12.2)        | 166,182 (214.2)     | 8770 (4.7) | 2280 (520.0) | 973  | 2.34 | 2.25-2.44 |
| >75 y     | 1,043,916 (8.2)         | 416,080 (797.2)     | 2658 (1.4) | 1459 (1097.4) | 1065 | 1.37 | 1.30-1.44 |
| ID group  |                        |                     |       |                     |     |       |       |
| Residential ID | –                       | –                   | 91,064 (48.7) | 7262 (159.5) | 2414 | 3.01 | 2.94-3.08 |
| Nonresidential | –                      | –                   | 27,007 (14.4) | 1621 (120.0) | 632  | 2.56 | 2.44-2.69 |
| Mild ID   | –                       | –                   | 69,078 (36.9) | 2219 (64.2) | 1046 | 2.12 | 2.03-2.21 |

Abbreviations: CI, confidence interval; GenPop, general Dutch adult population; ID, intellectual disability; IDpop, intellectual disability population; SMR, standardized mortality ratio.

<sup>a</sup>Crude mortality rate per 10,000 per year.
of dysphagia and choking problems. So far, no ID-specific treatment recommendations are available for clinicians to weigh these specific risks when they are considering treatment.

A potential third explanation for higher cancer mortality is less effective cancer care for people with ID than for other people. This is substantiated by our earlier finding that Dutch people with ID were given less cancer-related care than matched individuals without ID of the same age and sex. Other literature suggests that people with ID also participate poorly in screening programs, and this lowers their chances for early detection of cancer types targeted by screening. For all cancer types in the Dutch screening program (colon, cervical, and female breast), this study showed elevated mortality for people with ID in comparison with the general population. This underlines international concerns about access to and participation in population screening and shows the need to investigate this further.

The age disparity in cancer mortality between people with ID and the GenPop could be an indicator for late diagnoses, less extensive treatments, and suboptimal overall disease management. However, death at a younger age for people with ID should also be interpreted with respect to an earlier onset of aging and the occurrence of age-related diseases at a younger age in

### TABLE 2. Cancer-Related Mortality, 2015-2019

| GenPop (n = 12,677,678) | IDpop (n = 187,149) | SMR | 95% CI |
|------------------------|---------------------|-----|-------|
| Cancer-Related Deaths, No. (Rate) | Cancer-Related Deaths, No. (Rate) | Expected Deaths | SMR | 95% CI |
| Total cancer-related deaths | 228,120 (36.0) | 2408 (25.7) | 1623 | 1.48 | 1.42-1.54 |
| Sex | | | | |
| Males | 123,041 (39.7) | 1383 (25.8) | 1002 | 1.38 | 1.31-1.45 |
| Females | 105,079 (32.4) | 1025 (25.7) | 621 | 1.65 | 1.55-1.75 |
| Age at death, mean (SD), y | | | | |
| 18-24 y | 294 (0.4) | 23 (1.0) | 10 | 2.38 | 1.40-3.35 |
| 25-34 y | 1293 (1.3) | 47 (2.6) | 24 | 1.97 | 1.40-2.53 |
| 35-44 y | 5419 (4.9) | 201 (12.4) | 78 | 2.57 | 2.22-2.93 |
| 45-54 y | 20,040 (16.3) | 576 (31.0) | 300 | 1.92 | 1.76-2.08 |
| 55-64 y | 47,159 (44.8) | 866 (68.9) | 574 | 1.51 | 1.41-1.61 |
| 65-74 y | 71,843 (92.6) | 489 (111.5) | 421 | 1.16 | 1.06-1.26 |
| ≥75 y | 82,072 (157.2) | 206 (155.0) | 216 | 0.95 | 0.82-1.08 |

Neoplasm chapter

| Lip, oral cavity, and pharynx (C00-C14) | 3304 (0.5) | 50 (0.5) | 29 | 1.72 | 1.24-2.19 |
| Digestive organs (C15-C26) | 67,375 (10.6) | 778 (8.3) | 488 | 1.59 | 1.48-1.71 |
| Respiratory and intrathoracic organs (C30-C39) | 52,613 (8.3) | 518 (5.5) | 410 | 1.26 | 1.19-1.37 |
| Bone and articular cartilage (C40-C41) | 468 (0.1) | 5 (0.1) | 5 | 1.08 | 0.13-2.02 |
| Melanoma and other malignant neoplasms of skin (C43-C44) | 4459 (0.7) | 31 (0.3) | 36 | 0.85 | 0.55-1.15 |
| Mesothelial and soft tissue (C45-C49) | 3802 (0.6) | 27 (0.3) | 29 | 0.92 | 0.57-1.27 |
| Breast (C50) | 15,508 (2.4) | 151 (1.6) | 105 | 1.43 | 1.21-1.66 |
| Female genital organs (C51-C58) | 9519 (2.9) | 99 (2.5) | 58 | 1.70 | 1.37-2.04 |
| Male genital organs (C60-C63) | 14,239 (4.6) | 85 (1.6) | 84 | 1.01 | 0.79-1.22 |
| Urinary tract (C64-C68) | 13,771 (2.2) | 135 (1.4) | 94 | 1.44 | 1.20-1.69 |
| Eye, brain, and other parts of central nervous system (C69-C72) | 5086 (0.8) | 62 (0.7) | 54 | 1.15 | 0.86-1.43 |
| Thyroid and other endocrine glands (C73-C75) | 1008 (0.2) | 10 (0.1) | 8 | 1.29 | 0.49-2.08 |
| Ill-defined, secondary, and unspecified sites (C76-C80) | 11,041 (1.7) | 162 (1.7) | 63 | 2.58 | 2.18-2.98 |
| Primary of lymphoid, haematopoietic, and related tissue (C81-C96) | 17,478 (2.8) | 170 (1.8) | 115 | 1.48 | 1.26-1.70 |
| In situ neoplasms (D00-D09) | — | — | — | — | — |
| Benign neoplasms (D10-D36) | 8445 (1.3) | 125 (1.3) | 44 | 2.81 | 2.32-3.31 |
| Neoplasms of uncertain or unknown behavior (D37-D48) | 11,798 (1.9) | 104 (1.1) | 40 | 2.57 | 2.08-3.07 |

Abbreviations: CI, confidence interval; GenPop, general Dutch adult population; IDpop, intellectual disability population; SMR, standardized mortality ratio.

aCrude mortality rate per 10,000 per year.
bExpected counts have been rounded.

The chapter on neoplasms accounted for 32.4% of all deaths in the GenPop and for 22.4% of all deaths in the IDpop, with these being the most common cause of death in both groups. Circulatory and respiratory causes were second and third most common in both groups (GenPop, 26.5% and 8.8%, respectively; IDpop, 20.2% and 12.7%, respectively).
Because age is a strong predictor for developing cancer, early aging could then potentially also cause younger deaths from cancer. This might explain the higher mortality rates seen at relatively young ages in the IDpop, whereas SMRs declined with increasing age, and no mortality disparity due to cancer was observed above the age of 75 years. People with ID should then perhaps be compared not with their peers of the same age from the general population but rather with older age groups to match the same degree of aging and frailty. This would then also have implications for screening recommendations for people with ID (ie, starting at younger ages). Further research is needed to test this hypothesis and to specify what would be the most appropriate comparator age groups. In particular, we need more information about the age and staging at diagnosis, which would require linking data at the individual level to cancer registry data.

A limitation of this investigation of cancer-related deaths in the Dutch IDpop is that only proximate variables instead of actual ID diagnoses could be used. We used entitlements to national services that are open to people with ID diagnoses under the assumption that the utilization of these services and underlying supportive needs are indicative for ID severity. Both demographic and mortality patterns showed substantial differences between the IDpop and the GenPop; in particular, ID-specific causes of mortality were almost exclusively noted in the IDpop, and this confirmed accurate identification of ID cases. The subgroup with mild ID, however, underrepresented older people with mild ID and people with mild ID who did not use any of the available national supportive services. Consequently, these individuals were included in the GenPop and could potentially have contributed to an underestimation of the true cancer-related mortality in the population with mild IDs.

A major strength of the current study was that we were able to analyze mortality data from the complete Dutch adult population, including an entire ID subpopulation (ie, service users). It was not necessary to rely on smaller (convenience) samples, which have been criticized before for their limited generalizability in ID research. Moreover, all mortality data were processed in a standardized way with ICD-10 coding, and there was a relatively low amount of missing data (ie, unknown causes of death). However, the size of the ID subgroups and the length of the follow-up limited the possibilities for examining cancer-specific mortality within these subgroups. Future studies in this area also will require longer follow-up periods to investigate whether developments in cancer diagnostics and targeted cancer therapies will have similar (beneficial) effects within ID populations as they have in the general population.

In conclusion, cancer is the most prominent cause of death for people with ID and, in comparison with the

### TABLE 3. Most Common Cancer Type-Specific Causes, 2015-2019

| Cancer types with screening | GenPop (n = 12,677,678) | IDpop (n = 187,149) | SMR | 95% CI |
|-----------------------------|------------------------|--------------------|-----|-------|
| Colon (C18)                 | 18,298 (2.9)           | 200 (2.1)          | 121 | 1.66  | 1.43-1.89 |
| Breast (C50)                | 15,508 (2.4)           | 151 (1.6)          | 105 | 1.43  | 1.21-1.66 |
| Cervix uteri (C53)          | 2064 (0.3)             | 17 (0.2)           | 9   | 1.94  | 1.02-2.96 |
| Cancer types without screening | Bronchus and lung (C34) | 51,145 (8.1)       | 493 (5.3) | 398 | 1.24  | 1.13-1.35 |
|                              | Cancer without specification of site (C80) | 9585 (1.5)         | 138 (1.5) | 56 | 2.48  | 2.06-2.89 |
| Pancreas (C25)              | 14,047 (2.2)           | 128 (1.4)          | 103 | 1.24  | 1.03-1.46 |
| Esophagus (C15)             | 9345 (1.5)             | 126 (1.3)          | 81  | 1.56  | 1.29-1.84 |
| Other (ill-defined) digestive organs (C26) | 5091 (0.8)         | 77 (0.8)           | 29  | 2.65  | 2.06-3.25 |
| Bladder (C67)               | 6160 (1.0)             | 76 (0.8)           | 37  | 2.07  | 1.61-2.54 |
| Rectum (C20)                | 5664 (0.9)             | 74 (0.8)           | 43  | 1.71  | 1.32-2.10 |
| Prostate (C61)              | 13,955 (2.2)           | 71 (0.8)           | 81  | 0.91  | 0.70-1.12 |

**Abbreviations:** CI, confidence interval; GenPop, general Dutch adult population; IDpop, intellectual disability population; SMR, standardized mortality ratio.

*aCrude mortality rate per 10,000 per year.*

*bExpected counts have been rounded.*

*cAccording to the active population screening program in the Netherlands during the study period (2015-2019). Colon cancer screening was begun in 2014 and fully implemented in 2019. Prostate cancer, for example, also has screening opportunities (prostate-specific antigen testing) but is not part of population screening in the Netherlands.*
general population, is up to 1.5 times as likely to be the cause of death. In particular, relatively more deaths were caused by cancers targeted by the national screening program, digestive and bladder cancers, and cancers of unknown primary. Although data about the incidence of cancer among people with ID are currently inconclusive, these mortality disparities reveal a need for better tailoring of cancer screening and access to and receipt of cancer care for individuals with ID.

FUNDING SUPPORT
This study was funded by the Dutch Ministry of Health, Welfare, and Sport (grant 329574). The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing of this report.

CONFLICT OF INTEREST DISCLOSURES
Geraldine L. Leusink is a member of the board of directors for the Maastricht University Medical Center. The other authors made no disclosures.

AUTHOR CONTRIBUTIONS
Maarten Cuypers: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, writing—original draft, and writing—review and editing. Bianca W. M. Schalk: Formal analysis, methodology, writing—original draft, and writing—review and editing. Anne J. N. Boonman: Investigation, writing—original draft, and writing—review and editing. Jenneken Naaldenberg: Conceptualization, funding acquisition, supervision, writing—original draft, and writing—review and editing. Geraldine L. Leusink: Conceptualization, funding acquisition, supervision, writing—original draft, and writing—review and editing.

DATA AVAILABILITY
This study used nonpublic microdata from Statistics Netherlands. Under certain conditions, these microdata are accessible for statistical and scientific research (fee apply). Procedures can be found at https://www.cbs.nl/; for further information, email microdata@cbs.nl.

REFERENCES
1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16-27.
2. Hashim D, Boffetta P, La Vecchia C, et al. The global decrease in cancer mortality and incidence among individuals with Down syndrome. JAMA Intern Med. 2003;163:705-711.
3. Hill DA, Gridley G, Castrignius S, et al. Mortality and cancer incidence among individuals with Down syndrome. JAMA Intern Med. 2003;163:705-711.
4. Hogg J, Tuftfry-Wijne I. Cancer and intellectual disability: a review of some key contextual issues. J Appl Res Intellect Disabil. 2008;21:509-518.
5. Rubin G, Berendsen A, Crawford SM, et al. The expanding role of primary care in cancer control. Lancet Oncol. 2015;16:1231-1272.
6. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32:419-436.
7. Wullink M, Van Schrojenstein Lantman-de Valk HMJ, Dinant GJ, Mestemachers JFM. Prevalence of people with intellectual disability in the Netherlands. J Intellect Disabil Res. 2007;51:511-519.
8. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939-955.
9. Cheng H, Dharmadhikari AV, Varland S, et al. Truncating variants in NAA15 are associated with variable levels of intellectual disability, autism spectrum disorder, and congenital anomalies. Am J Hum Genet. 2018;102:985-994.
10. Villani A, Greer M-LC, Kalish JM, et al. Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk. Clin Cancer Res. 2017;23:v83-e90.
11. Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. Genet Med. 2016;18:1151-1157.
12. Patja K, Eero P, livanainen M. Cancer incidence among people with intellectual disability. J Intellect Disabil Res. 2001;45:300-307.
13. Sullivan SG, Hussain R, Threlfall T, Bittles AH. The incidence of cancer in people with intellectual disabilities. Cancer Causes Control. 2004;15:1021-1025.
14. Mansel J, Ericsson K. Deinstitutionalisation and Community Living: Intellectual Disability Services in Britain, Scandinavia and the USA. Springer; 2013.
15. Kiani R, Vahabzadeh A, Hepplewhite E, et al. Overcoming challenges in diagnosing and treating cancers in people with intellectual disability: a case analysis. Tizard Learning Disabil Rev. 2014;19:51-58.
16. Mason J, Scior K. ‘Diagnostic overshadowing’ amongst clinicians working with people with intellectual disabilities in the UK. J Appl Res Intellect Disabil. 2004;17:85-90.
17. Krah GL, Hammond L, Turner A. A cascade of disparities: health and health care access for people with intellectual disabilities. Ment Retard Dev Disabil Res Rev. 2006;12:70-82.
18. Michael J, Richardson A. Healthcare for all: the independent inquiry into access to healthcare for people with learning disabilities. Tizard Learning Disabil Rev. 2008;13:28-34.
19. Ali A, Scior K, Ratti V, Strydom A, King M, Hassiotis A. Discrimination and other barriers to accessing health care: perspectives of patients with mild and moderate intellectual disability and their carers. PLoS One. 2013;8:e70855.
20. Merten JW, Pomeranz JL, King JL, Moorhouse M, Wynn RD. Barriers to cancer screening for people with disabilities: a literature review. Disabil Health J. 2015;8:9-16.
21. Cuypers M, Tobi H, Huijmsmans CAA, et al. Disparities in cancer-related healthcare among people with intellectual disabilities: a population-based cohort study with health insurance claims data. Cancer Med. 2020;9:6888-6895.
22. Irwin KE, Henderson DC, Knight HP, Pirl WF. Cancer care for individuals with schizophrenia. Cancer. 2014;120:323-334.
23. Goss E, Lopez AM, Brown CL, Wollins DS, Brawley OW, Raghavan D. American Society of Clinical Oncology policy statement: disparities in cancer care. J Clin Oncol. 2009;27:2881-2885.
24. Hosking FJ, Carey IM, Shah SM, et al. Mortality among adults with intellectual disability in England: comparisons with the general population. Am J Public Health. 2016;106:1483-1490.
25. Glover G, Williams R, Hoslop P, Oyinolola J, Grey J. Mortality in people with intellectual disabilities in England. J Intellect Disabil Res. 2017;61:62-74.
26. Hoslop P, Blair PS, Fleming P, Hoghton M, Marriott A, Russ L. The Confidential Inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study. Lancet. 2014;383:889-895.
27. Cuypers M, Tobi H, Naaldenberg J, Leusink GL. Linking national public services data to estimate the prevalence of intellectual disabilities in the Netherlands: results from an explorative population-based study. Public Health. 2021;195:83-88.
28. Cuypers M, Schalk BWM, Koeks-Leenens MCJ, et al. Mortality of people with intellectual disabilities during the 2017/2018 influenza epidemic in the Netherlands: potential implications for the COVID-19 pandemic. J Intellect Disabil Res. 2020;64:482-488.
29. Cuypers M, Leijssen M, Bakker-van Gijssel EJ, et al. Patterns in the prevalence of diabetes and incidence of diabetic complications in people with and without an intellectual disability in Dutch primary care: insights from a population-based data-linkage study. Prim Care Diabetes. 2021;15:372-377.
30. Sargé D, Asmon A, Tetreau B, Sandberg M, Ahlström G. Cancer diagnoses among older people with intellectual disability compared with the general population: a national register study. J Intellect Disabil Res. 2020;64:579-588.
31. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165-169.
32. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428-1435.
33. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Peenen H. Gastric cancer. Lancet. 2016;388:2654-2664.
34. McGuire BE, Daly P, Smyth F. Lifestyle and health behaviours of adults with an intellectual disability. J Intellect Disabil Res. 2007;51:497-510.
35. Mysuru Shivanna L, Urooj A. A review on dietary and non-dietary risk factors associated with gastrointestinal cancer. J Gastrointest Cancer. 2016;47:247-254.
36. Duff M, Scheepers M, Cooper M, Hoghton M, Baddeley P. Helicobacter pylori: has the killer escaped from the institution? A possible cause of increased stomach cancer in a population with intellectual disability. J Intellect Disabil Res. 2001;45:219-225.
37. Kitchens DH, Binkley CJ, Wallace DL, Darling D. Helicobacter pylori infection in people who are intellectually and developmentally disabled: a review. Spec Care Dent. 2007;27:127-133.
38. Robertson J, Chadwick D, Baines S, Emerson E, Hatton C. Prevalence of dysphagia in people with intellectual disability: a systematic review. Intellect Dev Disabil. 2017;55:377-391.
39. Osborn DPJ, Horsfall L, Hassiots A, Petersen I, Walters K, Nazareth I. Access to cancer screening in people with learning disabilities in the UK: cohort study in the Health Improvement Network, a primary care research database. PLoS One. 2012;7:e3841.
40. Ouellette-Kuntz H, Coo H, Cobigo V, Wilton AS. Uptake of colorectal cancer screening among Ontarians with intellectual and developmental disabilities. PLoS One. 2015;10:e0118023.
41. Shin DW, Yu J, Cho J, et al. Breast cancer screening disparities between women with and without disabilities: a national database study in South Korea. Cancer. 2020;126:1522-1529.
42. Evenhuis HM, Hermans H, Hilgenkamp TIM, Bastiaanse LP, Echteld MA. Frailty and disability in older adults with intellectual disabilities: results from the Healthy Ageing and Intellectual Disability Study. J Am Geriatr Soc. 2012;60:934-938.
43. Janicki MP, Davidson PW, Henderson CM, et al. Health characteristics and health services utilization in older adults with intellectual disability living in community residences. J Intellect Disabil Res. 2002;46:287-298.
44. DePinho RA. The age of cancer. Nature. 2000;408:248-254.
45. Wolpert M, Rutter H. Using flawed, uncertain, proximate and sparse (FUPS) data in the context of complexity: learning from the case of child mental health. BMC Med. 2018;16:82.
46. Krahn GL, Fox MH. Health disparities of adults with intellectual disabilities: what do we know? What do we do? J Appl Res Intellect Disabil. 2014;27:431-446.
47. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023-1075.